Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 148 No. 2930 (2018)

Diagnosis and treatment of follicular lymphoma: an update

  • Mario Bargetzi
  • Reto Baumann
  • Sergio Cogliatti
  • Pierre-Yves Dietrich
  • Michel André Duchosal
  • Jeroen S. Goede
  • Felicitas Hitz
  • Carolin Konermann
  • Andreas Lohri
  • Ulrich Mey
  • Urban Novak
  • Alexandros Papachristofilou
  • Frank Stenner
  • Christian Taverna
  • Thilo Zander
  • Christoph Renner
DOI
https://doi.org/10.4414/smw.2018.14635
Cite this as:
Swiss Med Wkly. 2018;148:w14635
Published
24.07.2018

Summary

Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life. In addition to established regimens such as radiotherapy and immunochemotherapy, new treatment options are on the horizon. Furthermore, even the use of established chemotherapy agents has evolved, with new combinations moving to the forefront of the current treatment strategy. Nevertheless, there remains an unmet need for patients who have early relapses, those who are not responsive to anti-CD20 treatment regimens and for those in whom minimal residual disease persists even after immunochemotherapy. This review provides a summary of current developments in the diagnosis, treatment and management of follicular lymphoma, focusing on the clinical issues from a Swiss perspective.

References

  1. Mounier M, Bossard N, Remontet L, Belot A, Minicozzi P, De Angelis R, et al.; EUROCARE-5 Working Group; CENSUR Working Survival Group. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). Lancet Haematol. 2015;2(11):e481–91. doi:.https://doi.org/10.1016/S2352-3026(15)00155-6
  2. Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al.; EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931–42. doi:.https://doi.org/10.1016/S1470-2045(14)70282-7
  3. Anastasia A, Rossi G. Novel Drugs in Follicular Lymphoma. Mediterr J Hematol Infect Dis. 2016;8(1):e2016061.
  4. Cheah CY, Fowler NH. Novel agents for relapsed and refractory follicular lymphoma. Best Pract Res Clin Haematol. 2018;31(1):41–8. doi:.https://doi.org/10.1016/j.beha.2017.11.003
  5. Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M ; ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v83–90. doi:.https://doi.org/10.1093/annonc/mdw400
  6. Hitz F, Ketterer N, Lohri A, Mey U, Pederiva S, Renner C, et al. Diagnosis and treatment of follicular lymphoma. Swiss Med Wkly. 2011;141:w13247. doi:https://doi.org/10.4414/smw.2011.13247.
  7. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. doi:.https://doi.org/10.1182/blood-2016-01-643569
  8. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization 2017;Volume 2:Revised 4th edition.
  9. Vaidyanathan G, Czuczman MS. Follicular lymphoma grade 3: review and updates. Clin Lymphoma Myeloma Leuk. 2014;14(6):431–5. doi:.https://doi.org/10.1016/j.clml.2014.04.008
  10. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours). World Health Organization 2008:4th edition.
  11. Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27(7):1323–9. doi:.https://doi.org/10.1093/annonc/mdw185
  12. Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96(9):1327–34. doi:.https://doi.org/10.3324/haematol.2011.042531
  13. Takata K, Miyata-Takata T, Sato Y, Yoshino T. Pathology of follicular lymphoma. J Clin Exp Hematop. 2014;54(1):3–9. doi:.https://doi.org/10.3960/jslrt.54.3
  14. Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma - treatment and prognostic factors. Rev Bras Hematol Hemoter. 2012;34(1):54–9. doi:.https://doi.org/10.5581/1516-8484.20120015
  15. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055–63. doi:.https://doi.org/10.1182/blood-2015-11-624288
  16. Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology (Am Soc Hematol Educ Program). 2007;2007(1):216–25. doi:.https://doi.org/10.1182/asheducation-2007.1.216
  17. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al.; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. doi:.https://doi.org/10.1200/JCO.2013.54.8800
  18. Wöhrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol. 2006;17(5):780–4. doi:.https://doi.org/10.1093/annonc/mdl014
  19. Barrington SF, Mikhaeel NG. PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. Curr Hematol Malig Rep. 2016;11(3):185–95. doi:.https://doi.org/10.1007/s11899-016-0318-1
  20. Palacio C, Acebedo G, Navarrete M, Ruiz-Marcellán C, Sanchez C, Blanco A, et al. Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas. Haematologica. 2001;86(9):934–40.
  21. Graf BL, Korte W, Schmid L, Schmid U, Cogliatti SB. Impact of aspirate smears and trephine biopsies in routine bone marrow diagnostics: a comparative study of 141 cases. Swiss Med Wkly. 2005;135(9-10):151–9.
  22. Payne K, Wright P, Grant JW, Huang Y, Hamoudi R, Bacon CM, et al. BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma. Br J Haematol. 2011;155(1):84–92. doi:.https://doi.org/10.1111/j.1365-2141.2011.08803.x
  23. Einerson RR, Kurtin PJ, Dayharsh GA, Kimlinger TK, Remstein ED. FISH is superior to PCR in detecting t(14;18)(q32;q21)-IgH/bcl-2 in follicular lymphoma using paraffin-embedded tissue samples. Am J Clin Pathol. 2005;124(3):421–9. doi:.https://doi.org/10.1309/BLH8MMK85UBQ4K6R
  24. Camacho FI, Bellas C, Corbacho C, Caleo A, Arranz-Sáez R, Cannata J, et al. Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. Mod Pathol. 2011;24(5):698–707. doi:.https://doi.org/10.1038/modpathol.2010.237
  25. Bai B, Huang HQ. Individualized management of follicular lymphoma. Linchuang Zhongliuxue Zazhi. 2015;4(1):7.
  26. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65. doi:.https://doi.org/10.1182/blood-2003-12-4434
  27. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–22. doi:.https://doi.org/10.1016/S1470-2045(15)00169-2
  28. Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29):4480–4. doi:.https://doi.org/10.1200/JCO.2010.28.4786
  29. McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M, et al.; Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH); British Society for Haematology Committee. Guidelines on the investigation and management of follicular lymphoma. Br J Haematol. 2012;156(4):446–67. doi:.https://doi.org/10.1111/j.1365-2141.2011.08969.x
  30. Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–7. doi:.https://doi.org/10.1200/JCO.1997.15.3.1110
  31. Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30(27):3368–75. doi:.https://doi.org/10.1200/JCO.2011.40.6546
  32. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010;116(16):3843–51. doi:.https://doi.org/10.1002/cncr.25149
  33. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92. doi:.https://doi.org/10.1016/j.radonc.2011.05.013
  34. Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21(13):2474–80. doi:.https://doi.org/10.1200/JCO.2003.09.542
  35. Luthy SK, Ng AK, Silver B, Degnan KO, Fisher DC, Freedman AS, et al. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin’s lymphoma. Ann Oncol. 2008;19(12):2043–7. doi:.https://doi.org/10.1093/annonc/mdn529
  36. Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–63. doi:.https://doi.org/10.1016/S1470-2045(14)70036-1
  37. Buske C, Dreyling M, Herold M, Willenbacher W. Onkopedia guidelines: follicular lymphoma. https://wwwonkopedia-guidelinesinfo/en/onkopedia/guidelines/follicular-lymphoma/@@view/html/indexhtml 2012. Accessed 12 August 2017.
  38. Zimmermann M, Oehler C, Mey U, Ghadjar P, Zwahlen DR. Radiotherapy for Non-Hodgkin’s lymphoma: still standard practice and not an outdated treatment option. Radiat Oncol. 2016;11(1):110. doi:.https://doi.org/10.1186/s13014-016-0690-y
  39. Brady JL, Bonkley MS, Hajj C, et al. Outcome for curative radiotherapy for localised follicular lymphoma in the era of 18F-FDG PET-CT staging: an international collaborative study on behalf of ILROG. Hematol Oncol. 2017;35(S2). [Abstract 11].
  40. Alperovich A, Moskowitz C, Younes A, et al. Impact of PET Staging of Follicular Lymphoma on Treatment Outcomes and Prognosis. Blood 2017;ASH 59th Annual Meeting Abstracts:Abstract 1494.
  41. Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer. 2011;11(1):87. doi:.https://doi.org/10.1186/1471-2407-11-87
  42. Herfarth K, Witzens-Harig M. IF Bestrahlung und Rituximab im frühen Stadium des follikulären Lymphomas: 5 Jahres Daten des Heidelberger MIR Subkollektivs. Strahlenther Onkol. 2017;193(Suppl):S6.
  43. Macmanus MP, Fisher R, Roos D, O’Brien P, Macann A, Tsang R. CVP or R-CVP given after involved-field radiotherapy improves prograssion free survival in stage I-II follicular lymphoma: results of an international randmoized trial. Hematol Oncol. 2017;35(S2). [Abstract 12].
  44. Solal-Céligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848–53. doi:.https://doi.org/10.1200/JCO.2010.33.4474
  45. Yuda S, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto KI, et al. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann Hematol. 2016;95(12):2017–22. doi:.https://doi.org/10.1007/s00277-016-2800-1
  46. Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–35. doi:.https://doi.org/10.1016/S1470-2045(14)70027-0
  47. Castellino A, Santambrogio E, Nicolosi M, Botto B, Boccomini C, Vitolo U. Follicular Lymphoma: The Management of Elderly Patient. Mediterr J Hematol Infect Dis. 2017;9(1):e2017009. doi:.https://doi.org/10.4084/mjhid.2017.009
  48. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al.; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10. doi:.https://doi.org/10.1016/S0140-6736(12)61763-2
  49. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52. doi:.https://doi.org/10.1182/blood-2013-11-531327
  50. Flinn I, van der Jagt R, Chang J, et al. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2017;35(Suppl).
  51. Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–13. doi:.. Corrected in: J Clin Oncol. 2014;32(10):1095https://doi.org/10.1200/JCO.2012.45.0866
  52. Luminari S, Tarantino V, Anastasia A, et al. Long term results of the FOLLO5 randomized study comparing R-CVP with R-CHOP and R-FM as first line therapy in patients with advanced stage follicular lymphoma: A FIL study. Hematol Oncol. 2017;35(S2). [Abstract 15].
  53. Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin’s lymphoma: a practice guide for patient management. Oncologist. 2013;18(8):954–64. doi:.https://doi.org/10.1634/theoncologist.2013-0079
  54. Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet. 2013;381(9873):1163–5. doi:.https://doi.org/10.1016/S0140-6736(12)61965-5
  55. Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, et al. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study. Ann Hematol. 2016;95(7):1107–14. doi:.https://doi.org/10.1007/s00277-016-2668-0
  56. Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, et al. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57(4):880–7. doi:.https://doi.org/10.3109/10428194.2015.1091934
  57. Yamaguchi T, Morita T, Takahashi Y, Tsuda K, Mori J. Treatment for patients with indolent and mantle cell lymphoma. Lancet. 2013;382(9898):1094–5. doi:.https://doi.org/10.1016/S0140-6736(13)62018-8
  58. Colombat P, Brousse N, Morschhauser F, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analysis with extended follow-up (F/Up) of 7 years. ASH Annual Meeting Abstracts 2006;108:486.
  59. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97(1):101–6. doi:.https://doi.org/10.1182/blood.V97.1.101
  60. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416–23. doi:.https://doi.org/10.1182/blood-2003-10-3411
  61. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005;16(10):1675–82. doi:.https://doi.org/10.1093/annonc/mdi320
  62. Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–11. doi:.https://doi.org/10.1200/JCO.2014.59.5363
  63. Arora M, Gowda S, Tuscano J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol. 2016;7(4):209–21. doi:.https://doi.org/10.1177/2040620716652861
  64. Celgene. Celgene and LYSARC Provide Update on Phase III ‘RELEVANCE' Study of REVLIMID® in Combination with Rituximab (R2) for the Treatment of Previously Untreated Patients with Follicular Lymphoma. Press release 21 December 2017:http://ir.celgene.com/releasedetail.cfm?releaseid=1052524.
  65. Fowler N, Nastoupil L, de Vos S, et al. Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. Blood. 2016;128(22). [Abstract 1804].
  66. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331–44. doi:.https://doi.org/10.1056/NEJMoa1614598
  67. Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32(28):3096–102. doi:.https://doi.org/10.1200/JCO.2014.56.5853
  68. Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin Hematol. 2010;47(2):133–42. doi:.https://doi.org/10.1053/j.seminhematol.2010.01.003
  69. Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, et al.; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003–8. doi:.https://doi.org/10.1182/blood-2006-04-016725
  70. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27(10):1607–14. doi:.https://doi.org/10.1200/JCO.2008.17.1561
  71. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295–301. doi:.https://doi.org/10.1182/blood-2006-05-021113
  72. Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9(9):995–1001. doi:.https://doi.org/10.1023/A:1008416911099
  73. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51. doi:.https://doi.org/10.1016/S0140-6736(10)62175-7
  74. Salles G, Seymour JF, Feugier P, et al. Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. Blood. 2013;122:Abstract 509.
  75. Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, et al. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol. 2016;34(5):495–500. doi:.https://doi.org/10.1200/JCO.2015.61.3968
  76. Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, et al. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. Biol Blood Marrow Transplant. 2017;23(10):1631–40. doi:.https://doi.org/10.1016/j.bbmt.2017.05.021
  77. Casulo C, Friedberg JW, Ahn KW, Flowers CR, DiGilio A. Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: an NLCS and CIBMTS analysis. Hematol Oncol. 2017;35(S2). [Abstract 226].
  78. Illidge T, Morschhauser F. Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol. 2011;24(2):279–93. doi:.https://doi.org/10.1016/j.beha.2011.03.005
  79. Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, et al.; IDEC-C2B8 Study Group. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. Cancer Sci. 2011;102(9):1698–705. doi:.https://doi.org/10.1111/j.1349-7006.2011.02001.x
  80. Matsumoto K, Takayama N, Aisa Y, Ueno H, Hagihara M, Watanabe K, et al.; Keio BRB Study Group. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. Int J Hematol. 2015;101(6):554–62. doi:.https://doi.org/10.1007/s12185-015-1767-3
  81. Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, et al.; Study Group Indolent Lymphomas. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57–66. doi:.https://doi.org/10.1016/S1470-2045(15)00447-7
  82. Moita F, Esteves S, Klose T, Koehler M, Silva MG. Are Fludarabine Based Regimens Still Adequate for Relapsed/Refractory Follicular Lymphoma? An 18-Year Single-Center Experience. Ann Hematol Oncol. 2015;2(8):1059.
  83. MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016;23(6):407–17. doi:.https://doi.org/10.3747/co.23.3405
  84. Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–93. doi:.https://doi.org/10.1016/S1470-2045(16)30097-3
  85. Cheson BD, Trneny M, Bouabdallah K, et al. Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. Blood. 2016;128(22). [ASH Annual Meeting Abstracts].
  86. Barrientos JC. Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. Onco Targets Ther. 2016;9:2945–53. doi:.https://doi.org/10.2147/OTT.S102573
  87. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18. doi:.https://doi.org/10.1056/NEJMoa1314583
  88. Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33(31):3635–40. doi:.https://doi.org/10.1200/JCO.2014.59.9258
  89. Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31(26):3272–8. doi:.https://doi.org/10.1200/JCO.2012.48.3990
  90. Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. J Clin Oncol. 2016;34(22):2575–82. doi:.https://doi.org/10.1200/JCO.2015.65.7163
  91. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–58. doi:.https://doi.org/10.1200/JCO.2013.53.5229
  92. Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T, et al. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging. 2014;41(3):408–15. doi:.https://doi.org/10.1007/s00259-013-2441-8
  93. Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD, et al. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2017;58(4):809–15. doi:.https://doi.org/10.1080/10428194.2016.1213824
  94. Maciocia N, O’Brien A, Ardeshna K. Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection. N Engl J Med. 2016;375(17):1699–701. doi:.https://doi.org/10.1056/NEJMc1513288
  95. Mihăilă RG. Hepatitis C virus - associated B cell non-Hodgkin’s lymphoma. World J Gastroenterol. 2016;22(27):6214–23. doi:.https://doi.org/10.3748/wjg.v22.i27.6214
  96. Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404–10. doi:.https://doi.org/10.1093/annonc/mdu166
  97. Sultanik P, Klotz C, Brault P, Pol S, Mallet V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood. 2015;125(15):2446–7. doi:.https://doi.org/10.1182/blood-2014-12-618652
  98. Tees MT, Flinn IW. Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care? Curr Treat Options Oncol. 2017;18(3):16. doi:.https://doi.org/10.1007/s11864-017-0459-z

Most read articles by the same author(s)

1 2 3 > >>